Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
252 stopped studies mapped to Malignant Gastric Neoplasm and descendants · 88% state a reason
Over the 252 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04863430 | Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the… | Phase 2 | withdrawn | Apr 28, 2021 | Peking University | The anti-PD-1 agents were proved effective by several clinical trials and recommended to treat… | Other (stated, no rule matched) |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05296005 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | Phase 1 | withdrawn | Mar 25, 2022 | Ohio State University Comprehensive Cancer Center | PI Decision | Other (stated, no rule matched) |
| NCT06702384 | Molecular Analysis of Gastric and OEsophageal Cancers STudy(MAGnET) | — | withdrawn | Nov 25, 2024 | Royal Marsden NHS Foundation Trust | Never opened to recruitment due to lack of funding | Enrollment / accrual |
| NCT06341647 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | Phase 1 | withdrawn | Apr 2, 2024 | GC Cell Corporation | Determined that enrollment would be limited due to the change in care setting. | Enrollment / accrual |
| NCT02485834 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced… | Phase 2 | terminated | Jun 30, 2015 | Alliance for Clinical Trials in Oncology | Poor accrual | Enrollment / accrual |
| NCT04162665 | Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer | Phase 2 | terminated | Nov 14, 2019 | Washington University School of Medicine | Poor accrual and funding sponsor declared bankruptcy. | Enrollment / accrual |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid…(CONTRAST) | Phase 1 / Phase 2 | terminated | Sep 26, 2022 | BioInvent International AB | After the completion of phase IA, for business reasons it was decided to terminate the study. | Sponsor / business decision |
| NCT02867839 | Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced…(RESCUE-GC) | Phase 3 | terminated | Aug 16, 2016 | Peking University Cancer Hospital & Institute | The number of patients enrolled was much less than expected | Enrollment / accrual |
| NCT04508140 | Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver… | Phase 2 | terminated | Aug 11, 2020 | Highlight Therapeutics | Low recruitment rate | Enrollment / accrual |
| NCT04933227 | A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and… | Phase 2 | terminated | Jun 21, 2021 | Hoffmann-La Roche | Sponsor's decision to terminate the study after Stage 1; will not proceed with Stage 2. | Sponsor / business decision |
| NCT04937738 | Perioperative Chemotherapy in Gastric Cancer(PECORINO) | Phase 2 | terminated | Jun 24, 2021 | Ukrainian Society of Clinical Oncology | High rate of disease progression in XELOX arm | Other (stated, no rule matched) |
| NCT04294784 | Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in… | Phase 2 | terminated | Mar 4, 2020 | Huazhong University of Science and Technology | slow recruitment forcing early suspension of screening and enrollment | Enrollment / accrual |
| NCT05076591 | IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients… | Phase 1 | suspended | Oct 13, 2021 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Due to a business decision resulting in the deprioritization of this project and with no safety… | Safety / toxicity |
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid…(CAR) | Phase 1 | terminated | May 22, 2019 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT05056805 | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of… | N/A | withdrawn | Sep 27, 2021 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in… | Phase 1 / Phase 2 | terminated | Dec 24, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT04517448 | Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy(EQLVCPAL) | — | terminated | Aug 18, 2020 | Centre Hospitalier de la côte Basque | End of recruitment - Number of required subjects enrolled | Enrollment / accrual |
| NCT06206278 | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer… | Phase 2 | terminated | Jan 16, 2024 | LianBio LLC | Business Reason | Sponsor / business decision |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | May 29, 2020 | NextCure, Inc. | Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on… | Other (stated, no rule matched) |
| NCT01034670 | Advanced Gastrointestinal Endoscopic Imaging | N/A | terminated | Dec 17, 2009 | Stanford University | Change in personnel and cessation of funding | Funding |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03840967 | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated… | Phase 2 | terminated | Feb 15, 2019 | Shadia Jalal, MD | Due to slow accruals | Enrollment / accrual |
| NCT05354856 | The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer. | Phase 4 | terminated | May 2, 2022 | Rigshospitalet, Denmark | recruiting issues | Enrollment / accrual |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in…(FIDES-03) | Phase 1 / Phase 2 | terminated | Oct 27, 2020 | Basilea Pharmaceutica | Terminated prematurely for administrative reasons not related to patient safety. | Safety / toxicity |
| NCT05687617 | Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for… | Phase 2 | terminated | Jan 18, 2023 | Laval University | Recruitment lower than expected and negative results. | Enrollment / accrual |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04718402 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced… | Phase 1 | terminated | Jan 22, 2021 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT05101616 | A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally… | Phase 1 / Phase 2 | suspended | Nov 1, 2021 | Shanghai Minimally Invasive Surgery Center | difficult in enrolling participants | Enrollment / accrual |
| NCT05703555 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701(INTRUSION) | Phase 2 | withdrawn | Jan 30, 2023 | Erasmus Medical Center | Due to the decision to discontinue the global clinical development program of tusamitamab ravtansine | Other (stated, no rule matched) |
| NCT05233007 | Upper GI Serial Tumour Biopsies | — | suspended | Feb 10, 2022 | The Christie NHS Foundation Trust | To explore alternative funding streams | Funding |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT05579444 | Systems Biology of Gastrointestinal and Related Diseases | — | terminated | Oct 13, 2022 | Viome | Lack of enrollment. | Enrollment / accrual |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in… | Phase 1 | terminated | May 15, 2018 | Ipsen | Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Safety / toxicity |
| NCT02519140 | Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal… | Phase 3 | withdrawn | Aug 10, 2015 | Antonios Likourezos | not stated | Not stated |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT04977401 | EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection(EPSILON) | N/A | terminated | Jul 26, 2021 | Erasme University Hospital | Urgent Medical Device Product (ORISE Gel Submucosal Liftiong Agent) Removal by sponsor | Other (stated, no rule matched) |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic…(REGIRI) | Phase 1 / Phase 2 | terminated | Oct 26, 2018 | UNICANCER | Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate… | Safety / toxicity |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05043987 | Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With… | Phase 1 | withdrawn | Sep 14, 2021 | Conjupro Biotherapeutics, Inc. | New IND sponsor to initiate a separate study | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Mar 10, 2025source: clinicaltrials